Effect of Kangfuxin Liquid enema combined with mesalazine on gestational outcomes and quality of life in child-bearing female with active ulcerative colitis

A protocol for randomized, double-blind, controlled trial

Tong Wang, MD, Hua Lu, PhD, Fangyuan Li, PhD, Qi Zhang, PhD

Abstract

Background: In recent years, the incidence of ulcerative colitis (UC) is on the rise, and most of them are young adults. As the peak of the disease overlaps with the childbearing age, it has a great impact on the fertility of female patients. We, therefore, conduct a randomized and controlled trial to evaluate the efficacy and safety of mesalazine enteric-coated tablets combined with Kangfuxin Liquid (KFX) enema for the child-bearing period female with active UC.

Methods: In this randomized controlled study, a total of 236 eligible patients will be assigned to the experimental group (n = 118) or the control group (n = 118) in a 1:1 ratio. The control group will be taken mesalazine enteric-coated tablets combined with placebo enema and the experimental group will be taken mesalazine enteric-coated tablets combined with KFX enema. Participants will receive 8 weeks of intervention treatment and 3 months of maintenance treatment before pregnancy. The primary assessment is the Mayo score. Secondary outcomes include mucosal healing, faecal calprotectin (FC), Inflammatory Bowel Disease Quality (IBDQ), and pregnancy outcome.

Discussion: This study will provide evidence regarding the efficacy and safety of KFX enema used before pregnancy on halting active UC, reducing the relapse rate during pregnancy, improving pregnancy outcome, and the quality of life.

Trial registration: Chinese Clinical Trials Register identifier, ChiCTR2000039161, registered on October 20, 2020.

Abbreviations: A&D = anxiety and depression, CRF = case record form, FC = faecal calprotectin, IBD = inflammatory bowel diseases, IBDQ = Inflammatory Bowel Disease Quality, KFX = Kangfuxin Liquid, TCM = traditional Chinese medicine, UC = ulcerative colitis, VTE = venous thromboembolism.

Keywords: Kangfuxin Liquid, pregnancy outcome, randomized controlled trial, traditional Chinese medicine, ulcerative colitis

1. Introduction

Ulcerative colitis (UC) is one of the two inflammatory bowel diseases (IBD) characterized by bloody diarrhea, abdominal pain, and mucus stools. According to a systematic review, Europe has the highest annual incidence of UC—24.3 per 100,000 people. Although the number in Asia and the Middle East is only 6.3 per 100,000 people, in these countries such as Japan and China, the incidence of UC has been increasing remarkably. Not only the intestinal symptoms of UC itself but also its impact on all aspects of the daily life of patients, especially females, have received considerable critical attention. Of particular concern is that UC occurs most frequently in the young female with the highest incidence peak in the second or third decades of life which is the essential prime reproductive age for women.

In recent years, there has been an increasing amount of study on the impact of the female with UC on pregnancy and neonatal. Many pieces of evidence show that pregnant women with UC have a higher incidence rate of abnormal pregnancy and delivery, such as the delivery of premature, low birth weight infants, and venous thromboembolism (VTE) risk in both pregnancy and the postpartum period than those without UC, and there are
significant differences in active UC. Furthermore, female with UC increased the risk of infant birth defects overall. In a retrospective cohort study of 7798 cases of UC in Quebec, Canada between 1989 and 2016, UC was associated with 1.53 times the risk of central nervous system defects. Another study concluded that neonatal are at an elevated risk of limb and urinary defects. The problem about the damages of UC medication to their unborn children or heredity increases their fertility concerns. Guideline recommends that women plan to get pregnant when in remission. However, it cannot be ignored that an increased risk for UC relapse during pregnancy. Similarly, a meta-analysis by Abhyankar et al has demonstrated that the recurrence rate and severity of UC influenced by disease activity at the time of conception. In addition, several lines of evidence suggest that UC has an interactive relationship with Anxiety and Depression (A&D). Individuals with UC are at increased risk of A&D. Meanwhile, UC with comorbid A&D are more challenging to manage. The selective protective effect of antidepressant treatment on UC confirms that it has a two-way relationship with A&D. A prospective cross-sectional study in the United States or Denmark suggest that activity UC significantly correlated with sexual dysfunction. Besides, it exacerbates dysmenorrhea and gastrointestinal symptoms during menstruation. Overall, for females with UC, there are unique challenges in a different decade of life, spanning from menstruation, sexual health, mental health to fertility, and pregnancy. Consequently, it is essential for the patients to have optimal management of UC prior to and during pregnancy to achieve favorable maternal and neonatal outcomes, and preferable quality of life.

Mesalazine, a first-line treatment for mild to moderate UC, is recommended to continue to be used during pregnancy to reduce the significant increase of relapse rate. It is classified as Class B by the Food and drug administration which is safe and tolerable. However, there are still 23.6% to 36.5% of patients who have undergone standard treatment with mesalazine with unsatisfactory mucosal healing (endoscopy score ≥ 2) and even worsening of the symptom during the 12 months follow-up.

As integrative therapy or alternative medicine, traditional Chinese medicine (TCM) is safe and economical in improving symptoms. In recent decades, magnanimous evidence from clinicians suggests that TCM has some beneficial effects on UC. Kangfuxin Liquid (KFX) is an extract of Periplaneta americana dried worms, which has been approved by the National Medical Products Administration (Z51021834). Periplaneta americana is an insect of the cockroach family, recorded in Shen Nong Ben Cao Jing more than 2000 years ago in China, included many active substances such as polysols and peptide which presented the bioactive functions of anti-inflammation and promoting mucosal barriers repair. Periplaneta americana has been diffusely applied in China against various diseases. Modern research indicates that the Periplaneta americana prevents inflammatory responses to protects against renal and hepatic fibrosis, accelerates mucosal healing by increasing the expression of EGF and VEGF in granulation tissue. Over the past decade, it has been emphasized the effect of Periplaneta americana on the gastrointestinal ulcer. It is now well established that Periplaneta americana is effective and safe for gastrointestinal ulcer patients from a variety of studies including clinical trials, animal experiments, and system analysis. However, KFX treatment before pregnancy has not been evaluated in detail in terms of improving or maintaining the progression of UC from before, during pregnancy to childbirth. We designed an RCT to evaluate the effects of mesalazine combined with KFX enema before pregnancy on halting active UC, reducing the relapse rate during pregnancy, improving pregnancy outcome, and the quality of life.

2. Methods and analysis

2.1. Study design

This study is designed as a randomized, controlled, double-blind trial. With mesalazine enteric-coated tablets as the control, to explore the efficacy of mesalazine combined with KFX enema in the treatment of active UC in women with fertility requirements and to improve pregnancy outcome and quality of life, reduce the recurrence rate. Prospective participants will be asked to talk face to face with the researcher for a baseline screening visit after diagnosis. After the 8 weeks of treatment, they will be followed for another 3 months of maintenance therapy. This study will start in October 2020 and continue until April 2022. The study schedule is detailed in Table 1. The flowchart of the trial is shown in Figure 1.

2.2. Ethic approval

The research protocol is conducted in accordance with the principles of the Declaration of Helsinki and has been approved by the Sichuan Regional Ethics Review Committee on Traditional Chinese Medicine (approval no. 2019KL-072). Also, this trial has been registered in the Chinese Clinical Trial Registry (Registration No. ChiCTR2000039161).

2.3. Participants

A total of 236 women in the child-bearing period with UC will be recruited after signed the informed consent. They will be invited to the Department of gynecology, Teaching Hospital of Chengdu University of Traditional Chinese Medicine. The printed recruitment posters will be post in the hospital to recruit participants. All participants should meet the diagnostic criteria according to the Chinese consensus on the diagnosis and treatment of IBD. Eligible participants will be implemented randomly with a 1:1 allocation ratio in the control group with (n = 118) or the experimental group (n = 118).

2.4. Inclusion criteria

Patients who meet all of the following conditions will be considered for enrollment. The inclusion criteria are as follows:
1. Females, aged between 20 and 45 years;
2. Patients who meet the criteria of active UC refer to Chinese consensus on diagnosis and treatment;
3. Patients preparing for pregnancy;
4. Patients who willing to participate in the study, sign an informed consent and can be followed up

2.5. Exclusion criteria

The exclusion criteria are as follows:
1. Patients with infertility caused by diseases of reproductive system organs or male infertility;
The effective rate of the control group ranges from 41.25% to 76.47%, and the average rate is about 66.99%. We will use the following formula to estimate sample size:

\[
\frac{\pi_1(1-\pi_1)}{\pi_2(1-\pi_2)(\alpha^2 + \beta^2)}
\]

With a 5% significance level (\(\alpha = 0.05\)), 80% Power (\(\beta = 0.2\)), and 10% dropout rate, at least 118 patients should be enrolled in each group and 236 total participants will be recruited.

### 2.6. Sample size

The sample size was determined by the primary study results. According to previous reports, the effective rate of the experimental group based on the Mayo score ranges from 57.5% to 76.47% [22,35] and the average rate is about 66.99%. The effective rate of the control group ranges from 41.25% to 55.65% [22,37] and the average rate is about 48.45%. We will use the following formula to estimate sample size:

\[
\frac{\pi_1(1-\pi_1)/k + \pi_2(1-\pi_2)(\alpha_{1-\alpha}/2 + \beta)}{(\pi_1 - \pi_2)^2}
\]

With a 5% significance level (\(\alpha = 0.05\)), 80% Power (\(\beta = 0.2\)), and 10% dropout rate, at least 118 patients should be enrolled in each group and 236 total participants will be recruited.

### 2.7. Randomization and blinding

Participants will be randomly allocated according to a random list of numbers generated with SPSS21.0 software. Opaque envelopes containing an allocation sequence number will be used by an independent staff who needs to prepare the assignments and conceal the allocation sequence. Blinding will be strictly maintained to intervention staffs, participants, the statistician, and staff who obtained outcome measurement. They will not know the corresponding relations between numbers and different groups. By using an identical liquid placebo in color, consistency, and smell to the KFX, blinding will be ensured.

3. **Interventions**

In the experimental group, mesalazine enteric-coated tablets (supplied by LOSAN Pharma GmbH 0.5g/tablet) will be taken orally 1.0g per time and 3 times a day for 8 weeks continuously. At the same time, the KFX (supplied by Sichuan Good doctor Panxi Pharmaceuticals) will be given retention enema treatment 100mL per time, 1 time a day. KFX need to be heated to 37°C and poured into a one-time enema bag. The enema tube will be inserted into the anus for about 10 cm. The control group enteric-coated mesalazine tablets will be taken orally 1.0 g per time and 3 times a day for 8 weeks. The enema method of placebo is the same as that of the treatment group. During the treatment period, patients in both groups avoid irritant and crude fiber food and supplemented with an adequate amount of folic acid (2 mg/d). Eight weeks later, according to the guidelines[177], UC patients in remission (Mayo score ≤2 and normal intestinal mucosa or no active inflammatory) will continue to be treated with maintenance therapy. Maintenance therapy is based on the treatment mentioned above, but the dose is reduced (mesalazine 0.5 g/time, 3 times/day, KFX/placebo enema 50mL) for 3 months. Subsequently, the patient in stable condition will be given active pregnancy guidance. Both groups of patients change to oral mesalazine (0.5 g/time, 3 times/day) from pregnancy to delivery. Due to a lack of research on the safety of KFC being used during pregnancy, KFX will be discontinued once patients in remission enter the active pregnancy preparations stage. All drugs should be the same lot number. In the course of the study, it is forbidden to add other drugs or interventions that may interfere with the trial. Cases in which symptoms have not alleviated or even aggravates, the participants voluntarily withdraw, and no medication or any follow-up records due to poor compliance will be regarded as excluded cases, and participants will be required to complete the assessments as much as possible.
Recruiting

Screening for eligibility

19 eligible participants

randomization

control group(n=118)
Mesalazine + placebo enema for 8 weeks

experimental group(n=118)
Mesalazine + KFX enema for 8 weeks

outcomes evaluation

According to Mayo score and mucosal healing

Quiescent UC

maintenance therapy for 3 months
Provide pregnancy guidance

Active UC

Continue intervention until in remission or deadline for research

Follow-up until delivery

Data analysis

Figure 1. Trial flow chart.
4. Outcome measures

4.1. Primary outcome

The primary outcome in this trial is the Mayo score at baseline, after an 8-week intervention, and 3-month remission period maintenance therapy.

The Mayo score scoring standard is based on references\(^{[38]}\) (Table 2). A total score of ≤2 is divided into symptom relief, 3 to 5 is divided into mild activity, 6 to 10 is divided into moderate activity, and 11 to 12 is divided into severe activity.

### Table 2
Mayo scoring system for assessment of ulcerative colitis activity.

| Score | Stool frequency A | Bloody stools B | Colonoscopy | Physician’s global assessment C |
|-------|-------------------|-----------------|-------------|---------------------------------|
| 0     | Norma (no. of stools for this patient) | No blood seen | Normal or inactive disease | Normal |
| 1     | 1–2 times more than normal | Streak of blood with stool less than half the time | Mild disease (erythema, decreased vascular pattern, mild friability) | Mild |
| 2     | 3–4 times more than normal | Obvious blood with stool most of the time | Moderate disease (marked erythema, lack of vascular pattern, friability, erosions) | Moderate |
| 3     | 5 or more times more than normal | Blood alone passes | Severe disease (spontaneously bleeding, ulceration) | Severe |

The Modified Mayo score ranges from 0 to 12, with higher scores indicating a more severe condition. (A) Each patient serves as her own control to establish the degree of abnormality of the stool frequency. (B) The daily bleeding score represents the most severe bleeding of the day. (C) The physician’s global assessment acknowledges the three other criteria, the patient’s daily recollection of abdominal discomfort and a general sense of wellbeing, and other observations, such as physical findings and the patient’s performance status.

4.2. Secondary outcomes

The secondary outcomes include:

1. pregnancy outcome
   - Pregnancy outcome include pregnancy rate (%), abnormal pregnancy rate (%), and live birth rate (%). In this study, abnormal pregnancy is defined as any of the following: abortion, threatened abortion, premature delivery, delivery of a low-birth-weight infant, VTE, and congenital defect, etc.—any pregnancy-related event causing illness in the mother or fetus.
   - Patients with remission UC can be seen as normal colon mucosal appearance, pseudopolyp formation, or scar-like changes.

2. mucosal healing rate (%)

3. IBDQ
   - The patients’ quality of life is evaluated by the IBDQ\(^{[39]}\) included the 32 items and divided into 4 modules: bowel symptoms, systemic symptoms, emotional function, and social function. Each question has graded responses from 1 to 7, and thus scored from 32 to 224 points, with a higher score indicates a better quality of life.

4. FC
   - Endoscopies as the “gold standard” determine the presence of mucosal inflammation in the bowel. Some studies propose that endoscopy should be used with caution during pregnancy to avoid adverse pregnancy outcomes.\(^{[40,41]}\) Therefore, for the noninvasive monitoring of the activity or relapse of UC, the FC will be measured to replace endoscopy after pregnancy. The concentration of FC has a strong correlation with the level of intestinal inflammatory activity during pregnancy.\(^{[42]}\)

4.3. Safety outcomes

KFX has been used clinically for many years and has satisfactory safety profiles. To monitor the adverse reactions, Safety evaluation will include electrocardiogram, routine examination, blood routine test, hepatic function, renal function, urine routine test, and stool routine test. All safety results will be evaluated at baseline, 8th, 20th week after the intervention, 0th, 4th, 7th month, and until delivery after pregnancy.

If any adverse event occurs including toxicity and side effects, researchers should record it in the case record form (CRF) in detail and provide a proper treatment emergently. A serious adverse event will be reported to the ethical committee within 24 h. In addition, the patient will be determined whether to terminate the trial based on the severity.

4.4. Quality control and trial monitoring

In order to maintain the quality of the study, all researchers will accept specialized training including how to select and exclude participants, how to correctly manipulate intervention measures, how to fill the case report forms uniformly, how to evaluate outcomes, and manage data. The trial data of the patient will be recorded in the case record and then input into the spreadsheet respectively by 2 data managers. Once the CRF is completed, the data will be locked and not to be allowed to modify. To guarantee the objectivity of the data, the data managers submit it to the statistician for statistical analysis blinded during the trial.

4.5. Statistical analysis

The statistician performs Statistical analyses of data by using SPSS21.0 software (International Business Machines Corp., Armonk, NY). Intention-to-treat principle approach for efficacy and safety analysis will be used. As dealing with the missing values, multiple imputations method will be applied. Continuous variables with normal distribution, expressed as Mean± Standard Deviation, will be analyzed by t test. In contrast, nonparametric tests will be adopted when variables are kept in the abnormal distribution. Categorical data presented by frequency and percentage will be analyzed by the chi-square test or Fisher exact test. All the tests will be conducted two-sided, and a P-value < .05 will be considered as the significant level.

5. Discussion

Up to now, the etiology of UC has not been fully elucidated. Genetics, environmental factors, autoimmunity, and gut microbiota are generally considered to be key risk factors for UC. Research by analyzing the intestinal bacterial community indicates that UC patients have intestinal dysbiosis with
reduction of biodiversity. In particular, Firmicutes and Bacteroidetes known to promote gut health have been reduced most significantly. Moreover, the impaired epithelial barrier is caused by key pro-inflammatory cytokines (tumor necrosis factor-α (TNF-α), interferon (IFN)-γ, interleukin (IL)-13, etc) is a pathogenic factor for UC. In recent years, Mitochondriopathy is considered to be the pathogenic process in UC, loss of mitochondrial homeostasis brings about defective energy production, increased mitochondrial oxidative stress, and the release of pro-inflammatory DAMPs 1 molecule.

Generous studies based on UC mouse models trials show that Periplaneta americana increases the Lactobacillales in UC mouse, decreases E. coli intestinal bacteria translocation, modulate the flora structure, restore the intestinal-immune system, stimulate fibroblasts proliferation and accumulate collagen significantly to promote the colonic morphology and mucosal barrier recovery. Simultaneously, Periplaneta americana improves the accumulation of myeloperoxidase (malondialdehyde, superoxide dismutase, catalase, and nitric oxide), reduce inflammatory factor expression (TNF-α, IL-6, MMP-9, and MMP-2), and block the MAPK/NF-κB signaling pathway. Currently, high-quality research and evidence are lacking in KFX for the female with fertility requirements. Therefore, we conduct a randomized and controlled trial to evaluate the efficacy and safety of mesalazine combined with KFX enema before pregnancy in the treatment of active UC in women with fertility requirements and to improve pregnancy outcome and quality of life, reduce the recurrence rate. In particular, we use the FC instead of endoscopic examination which is not suggested to be used to assess the symptom progression of the UC during the pregnancy. We hope the results clarify the value of KFX as the adjunctive therapy for a child-bearing period female with active UC.

5.1. Trial status

The recruitment of patients started on October 30, 2020, and it is expected that by January 30, 2021, the required sample size will be reached. This protocol was submitted before completion of recruitment.

Acknowledgments

We would like to thank all the patients who will participate in the trial and the staff for their support.

Author contributions

Conceptualization: Tong Wang, Hua Lu.
Investigation: Fangyuan Li, Qi Zhang.
Supervision: Hua Lu.
Writing – original draft: Tong Wang.
Writing – review & editing: Tong Wang.

References

[1] Li F, Qi Z, Hua L, et al. The efficacy of acupuncture for the treatment and the fertility improvement in child-bearing period female with Hashimoto Disease: a randomized controlled study. Medicine (Baltimore) 2020;99:e20909.
[2] Chow DK, Leong RW, Tsoi KK, et al. Long-term follow-up of ulcerative colitis in the Chinese population. Am J Gastroenterol 2009;104:647–54.
[3] Murakami Y, Nishiaki Y, Obu MS, et al. Estimated prevalence of ulcerative colitis and Crohn’s disease in Japan in 2014: an analysis of a nationwide survey. J Gastroenterol 2019;54:1070–7.
[4] Langholz E, Munkholm P, Nielsen OH, et al. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 1991;26:1247–56.
[5] Stephansson O, Larsson H, Pedersen L, et al. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis 2011;17:795–801.
[6] Iro A, Iinaka B, Omori T, et al. Relationship between the Clinical Course of Ulcerative Colitis during Pregnancy and the Outcomes of Pregnancy: a retrospective evaluation. Intern Med 2018;57:159–64.
[7] Kim YH, Pfäffl B, Larson A, et al. The risk of venous thromboembolism in women with inflammatory bowel disease during pregnancy and the postpartum period: a systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e17309.
[8] Ornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007;56:830–7.
[9] Norgård B, Pulho E, Pedersen L, et al. Risk of congenital abnormalities in children born to women with ulcerative colitis: a population-based, case-control study. Am J Gastroenterol 2003;98:2006–10.
[10] Gawron LM, Goldberger AR, Gawron AJ, et al. Disease-related pregnancy concerns and reproductive planning in women with inflammatory bowel diseases. J Fam Plann Reprod Health Care 2015;41:272–7.
[11] Rolston VS, Boroujerdi L, Long MD, et al. The influence of hormonal fluctuation on inflammatory bowel disease symptom severity—a cross-sectional study. Inflamm Bowel Dis 2019;24:387–93.
[12] Abhyankar A, Ham M, Moss AC. Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013;38:460–6.
[13] Nazabi S, Gorregati VS, Yadav S, et al. Influences and impact of anxiety and depression in the setting of inflammatory bowel disease. Inflamm Bowel Dis 2018;24:2303–8.
[14] Frolkis AD, Vallerand IA, Shaheen AA, et al. Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression. Gut 2019;68:1606–12.
[15] de Silva PS, O’Toole A, Marc LG, et al. Development of a sexual dysfunction scale for women with inflammatory bowel disease. Inflamm Bowel Dis 2018;24:2350–9.
[16] Bharadwaj S, Kulkarni G, Shen B. Menstrual cycle, sex hormones in female inflammatory bowel disease patients with and without surgery. J Dig Dis 2015;16:245–55.
[17] Nguyen GC, Seow CH, Maxwell C, et al. The Toronto Consensus Statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology 2016;150:734–57.e1.
[18] Uijhara M, Ando T, Ishiguro K, et al. Importance of appropriate pharmacological management in pregnant women with ulcerative colitis (J): BMC Res Notes 2013;6:210.
[19] Ruben DT, Bradette M, Gabalec L, et al. Ulcerative colitis remission status after induction with mesalazine predicts maintenance outcomes: the MOMENTUM trial. J Crohns Colitis 2016;10:925–33.
[20] Ogata H, Aoyama N, Mizushima S, et al. Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study. Intest Res 2017;15:368–79.
[21] Kou FS, Shi L, Li JX, et al. Clinical evaluation of traditional Chinese medicine on mild active ulcerative colitis: a multi-center, randomized, double-blind, controlled trial. Medicine (Baltimore) 2020;99:e21903.
[22] Gong Y, Zha Q, Li L, et al. Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: a double-blinded and randomized study. J Ethnopharmacol 2012;141:592–8.
[23] Singla V, Pratap Mouli V, Garg SK, et al. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis—a randomized, placebo-controlled, pilot study. J Crohns Colitis 2014;8:208–14.
[24] Lu N. Study on the quality control of the chemical constituents of Periplaneta americana and its preparation Kangfuxin[D]. Peking Union Medical College; 2017.
[25] Li D, Li W, Chen Y, et al. Anti-inflammatory activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013;38:460–6.
[26] Liu J, Zhou L, He L, et al. Periplaneta Americana extract may attenuate intestinal bacteria translocation, modulate the E coli inflammatory DAMPs1 molecular. Inflamm Bowel Dis 2018;24:387–93.
[27] Li L, Wang MZ, Yuan TJ, et al. The crude ethanol extract of Periplaneta americana L. stimulates wound healing in vitro & in vivo. Chin Med 2019;14:33.

[28] Lu S, Wu D, Sun G, et al. Gastroprotective effects of Kangfuxin against water-immersion and restraint stress-induced gastric ulcer in rats: roles of antioxidation, anti-inflammation, and pro-survival. Pharm Biol 2019;57:770–7.

[29] Ren PW, Yang WJ, Wang DD, et al. Kangfuxinye enema combined with mesalamine for ulcerative colitis: a systematic review and GRADE approach. Evid Based Complement Alternat Med 2017;2017:6019530.

[30] Li N, Lu R, Yu Y, et al. Protective effect of Periplaneta americana extract in ulcerative colitis rats induced by dinitrochlorobenzene and acetic acid. Pharm Biol 2016;54:2560–7.

[31] Ma X, Hu Y, Li X, et al. Periplaneta americana Ameliorates Dextran sulfate sodium-induced ulcerative colitis in rats by Keap1/Nrf-2 activation, intestinal barrier function, and gut microbiota regulation. Front Pharmacol 2018;9:944.

[32] Xue P, Wang L, Xu J, et al. Temperature-sensitive hydrogel for rectal perfusion improved the therapeutic effect of Kangfuxin liquid on DDS-induced ulcerative colitis mice: the inflammation alleviating and the colonic mucosal barriers repair. Int J Pharm 2020;589:119846.

[33] Idänpään-Heikkilä JE. Ethical principles for the guidance of physicians in medical research—the Declaration of Helsinki. Bull World Health Organ 2001;79:279.

[34] Wu KC, Liang J, Ran ZH, et al. Chinese consensus on diagnosis and treatment of inflammatory bowel disease (Beijing, 2018). Chin J Pract Intern Med 2018;38:796–813.

[35] Su Y. Efficacy of oral mesalazine combined with Kangfuxin liquid retention enema in the treatment of ulcerative colitis[J]. Chin Geriatr Healthc Med 2019;17:77–80.

[36] Ouyang W, Ran H. Clinical observation of mesalazine combined with Kangfuxin liquid in the treatment of ulcerative colitis[J]. Chin J Integr Tradit Chin Western Med Digest 2014;22:400–1.

[37] Sun J, Yuan Y. Mesalazine modified-release tablet in the treatment of ulcerative colitis in the active phase: a Chinese, multicenter, single-blind, randomized controlled study. Adv Ther 2016;33:400–9.

[38] Schroeder KW, Tremaine WJ, Istrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New Engl J Med 1987;317:1623–2162.

[39] Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804–10.

[40] De Lima A, Galjart B, Wisse PH, et al. Does lower gastrointestinal endoscopy during pregnancy pose a risk for mother and child?—A systematic review. BMC Gastroenterol 2015;15:1310.

[41] Ludvigsson JF, Lebwohl B, Ekborn A, et al. Outcomes of pregnancies for women undergoing endoscopy while they were pregnant: a nationwide cohort study. Gastroenterology 2017;152:554–63, e9.

[42] Kammerlander H, Nielsen J, Kjeldsen J, et al. Fecal calprotectin during pregnancy in women with moderate-severe inflammatory bowel disease. Inflamm Bowel Dis 2018;24:839–48.

[43] Sokol H, Lay C, Seksik P, et al. Analysis of bacterial bowel communities of IBD patients: what has it revealed? Inflamm Bowel Dis 2008;14:858–67.

[44] Backhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine. Science 2005;307:1915–20.

[45] Ho GT, Aird RE, Liu B, et al. MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation. Mucosal Immunol 2018;11:120–129.

[46] Watson CJ, Hoare CJ, Garrod DR, et al. Epithelial apoptosis is a prominent feature of the epithelial barrier disturbance in intestinal inflammation: effect of proinflammatory interleukin-13 on epithelial cell function. Mucosal Immunol 2008;1(Suppl 1):S58–63.

[47] De Lima A, Galjart B, Wisse PH, et al. Does lower gastrointestinal endoscopy during pregnancy pose a risk for mother and child?—A systematic review. BMC Gastroenterol 2015;15:1310.

[48] Boyapati RK, Dorward DA, Tamborska A, et al. Mitochondrial DNA is a predominant feature of the epithelial barrier disturbance in intestinal inflammation: effect of proinflammatory interleukin-13 on epithelial cell function. Mucosal Immunol 2018;11:120–30.

[49] uvallet C, Gibbons SM, Gurry T, et al. Meta-analysis of gut microbiome during pregnancy in women with moderate-severe inflammatory bowel disease. Inflamm Bowel Dis 2018;24:2113–22.

[50] Kugathasan S, Denson LA, et al. Treatment-naive inflammatory bowel disease. Cell Host Microbe 2014;15:382–92.

[51] Nguyen T, Chen X, Chai J, et al. Antiinflammatory and gut microbiota composition in new-onset Crohn’s disease. Cell Host Microbe 2014;15:382–92.